These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 26089887)

  • 1. CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.
    Ghetti G; Pradelli L; Papageorgiou G; Karpouzos G; Arikan Y
    Clinicoecon Outcomes Res; 2023; 15():97-109. PubMed ID: 36825076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of type 2 diabetes in Iran: A cost-of-illness study.
    Jalilian H; Heydari S; Imani A; Salimi M; Mir N; Najafipour F
    Health Sci Rep; 2023 Feb; 6(2):e1120. PubMed ID: 36824619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece: results from the diabetes registry.
    Souliotis K; Koutsovasilis A; Vatheia G; Golna C; Nikolaidi S; Hatziagelaki E; Kotsa K; Koufakis T; Melidonis A; Papazafiropoulou A; Tentolouris N; Siami E; Sotiropoulos A
    BMC Endocr Disord; 2020 Jan; 20(1):16. PubMed ID: 31992275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece.
    Kousoulakou H; Hatzikou M; Baroutsou V; Yfantopoulos J
    Cost Eff Resour Alloc; 2017; 15():19. PubMed ID: 28904527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus.
    Didangelos T; Tziomalos K; Margaritidis C; Kontoninas Z; Stergiou I; Tsotoulidis S; Karlafti E; Mourouglakis A; Hatzitolios AI
    J Diabetes Res; 2017; 2017():6719239. PubMed ID: 28373993
    [No Abstract]   [Full Text] [Related]  

  • 6. Costs of Managing Patients with Diabetes in a Large Health Maintenance Organization in Israel: A Retrospective Cohort Study.
    Porath A; Fund N; Maor Y
    Diabetes Ther; 2017 Feb; 8(1):167-176. PubMed ID: 27853980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost of Managing Type 2 Diabetes Mellitus in Greece: A Retrospective Analysis of 10-Year Patient Level Data "The HERCULES Study".
    Migdalis I; Rombopoulos G; Hatzikou M; Manes C; Kypraios N; Tentolouris N
    Int J Endocrinol; 2015; 2015():520759. PubMed ID: 26089887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the cost of Type II diabetes in Europe.
    Jönsson B
    Diabetologia; 2002 Jul; 45(Suppl 1):S5-S12. PubMed ID: 27942782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study).
    Rombopoulos G; Hatzikou M; Latsou D; Yfantopoulos J
    Hormones (Athens); 2013; 12(4):550-8. PubMed ID: 24457403
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.